October 05, 2020 Few clues to flotation fever in past performance Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
April 11, 2018 Another venture funding surge sets up a strong 2018 Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
April 09, 2018 First-quarter floats hold amid uncertain climate Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.